Adult patients on extracoporeal membrane oxygenation (ECMO) frequently experience bleeding,
which is in part caused by acquired von Willebrand syndrome (vWS). Prior in vitro studies
have shown that the addition of recombinant von Willebrand Factor (vWF) to ECMO patient blood
samples, normalizes platelet adhesion and thrombus formation. This study is a phase I study,
where adult ECMO patients with refractory bleeding will be treated with recombinant vWF a
single time. The primary objectives are to evaluate the safety, tolerability, and
pharmacokinetics of recombinant vWF in adult ECMO patients.